TY - JOUR T1 - Impact and outcome of COVID-19 on SSc-ILD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA2531 VL - 58 IS - suppl 65 SP - PA2531 AU - Anna Maria Hoffmann-Vold AU - Cathrine Brunborg AU - Francesca Tirelli AU - Patricia E Carreira AU - Nicoletta Del Papa AU - Arsène Mekinian AU - Madelon Vonk AU - Alessandro Giollo AU - Giacomo De Luca AU - Maria De Santis AU - Corrado Campochiaro AU - Carina Mihai AU - Paolo Airo AU - Maria-Grazia Lazzaroni AU - Elisabetta Zanatta AU - Rosario Foti AU - Yannick Allanore AU - Daniel E. Furst AU - Marco Cerinic-Matucci AU - Armando Gabrielli AU - Oliver Distler Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA2531.abstract N2 - Background: Interstitial lung disease (ILD) has shown to worsen outcome in patients with Coronavirus disease-19 (COVID-19). Systemic sclerosis (SSc) is a severe, multi-organ disease associated with ILD.Objectives: To assess factors associated with severe outcome in SSc-ILD from European Scleroderma Trial and Research (EUSTAR).Methods: SSc patients from EUSTAR with COVID-19 were prospectively collected between 15.03.-31.12.2020. Severe outcome was defined as need of ventilation/ECMO or death. Risk factors evaluated were sex, age, comorbidities, immunosuppressive treatment, SSc subtype, autoantibodies, and other SSc associated organ manifestations. Descriptive statistics and logistic regression models were applied.Results: Among 178 SSc patients with COVID-19, 90 (51%) had ILD. Mean age of SSc-ILD patients was 59 years, 24 (27%) were male and 33 (37%) had >1 non-SSc associated comorbidity. At COVID-19 infection, 2 (8%) SSc-ILD patients used Prednisone>10mg; 4 (15%) MTX, 3 (12%) Azathioprine, 10 (39%) Mycophenolate and 5 (19%) Rituximab. Over median 5.5 weeks, 26/90 (29%) developed a severe outcome, including 17 (20%) deaths. Older age, male sex, non-SSc comorbidities and SSc associated renal or cardiac disease were associated with severe outcome in univariable logistic regression (figure).Conclusion: SSc-ILD patients with COVID-19 have a high risk of mortality. Male patients, older age, non-SSc comorbidities and other SSc organ manifestations risk a more severe outcome.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2531.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -